TORRANCE, CA--(Marketwired - August 18, 2016) - Neoteryx LLC, a Phenomenex spin-off company which develops and manufactures technologies and products for the collection of biological fluids, is celebrating its second anniversary with a flourishing presence in medical research.
Phenomenex President and CEO Fasha Mahjoor developed Neoteryx at the suggestion of a colleague in England, who observed the challenges pharmaceutical companies faced collecting adequate fluid samples in small animal studies and pediatric applications. In the summer of 2014, the start-up's flagship product Mitra® was launched.
The microsampling device collects precisely 10 or 20 microliters of fluid, employing Volumetric Absorptive Microsampling (VAMS™) technology-a dried sample collection technique developed through collaborative efforts between Neoteryx and major American and European pharmaceutical companies. As of last week, Mitra is being used in five human clinical trials.
"In our short history, that's very fast," Neoteryx Senior Business Development Manager Kelvin Lin said. "We are in 10 of the 10 major pharmaceutical companies, as well as major universities, clinical labs and medical centers around the world." The microsampling device has also been featured at some of the industry's most distinguished conferences.
"Consultant and clinical chemistry fellows from the Mayo Clinic and other major clinically-focused organizations in the US presented their work on this device at MSACL [Mass Spectrometry: Applications to the Clinical Lab] this year," Neoteryx President Bert Rietveld added. "Large organizations have been testing this product and proving to themselves that it works."
While Mitra was originally intended for pharmaceutical research purposes, Mahjoor and his team have learned it has "far, far greater use" for clinical labs, doctors, and patients themselves.
"Rather than give up lots of time and blood at the lab or doctor's office, you could use a Mitra device at home, drop it in the post, and be done in seconds," Mahjoor explains. "This device is a much welcomed innovation in ease and efficiency that will change how and where blood is currently drawn, and has been for years."
Click here to read the full feature article on Neoteryx from Herald Publications.
Neoteryx LLC, a spin-off of Phenomenex, Inc., is an independent company that is focused on delivering simple, quantitative, and automatable microsampling solutions for biological samples which improve animal and patient welfare, reduce laboratory costs, and enable convenient sample collection anywhere, anytime, by anyone. Neoteryx customers do their work across the biological spectrum, working to advance pharmaceutical development, personalized medicine, biotechnology research, and clinical diagnostics. For more information on Neoteryx, visit www.neoteryx.com.
The Mitra Microsampler class I medical device is for direct specimen collection of blood and other biological fluids. It is not specific to any clinical test, and is not for use in diagnostic procedures. Use of the Mitra Microsampler in Laboratory Developed Tests (LDTs) requires further processing including the establishment of performance characteristics and successful validation by the laboratory in a manner consistent with CLIA requirements.
Image Available: http://www.marketwire.com/library/MwGo/2016/8/17/11G111012/Images/blood-draw-9cee324c928a8ab68521bdea632d470a.jpg
Image Available: http://www.marketwire.com/library/MwGo/2016/8/17/11G111012/Images/neoteryx_mitra-36134330d75fa0a6b5ee70ae1b1cb672.jpg